Tag: Eculizumab

The landscape of myasthenia gravis (MG) treatment has evolved beyond traditional immunosuppressants to include advanced, targeted injectable therapies. These newer options, including both subcutaneous injections and intravenous infusions, target specific components of the immune system to manage symptoms more effectively and improve quality of life.

Approximately 85% of generalized myasthenia gravis cases are driven by an immune system attack, highlighting the role of complement inhibitors like Eculizumab and avacopan. What is the difference between Eculizumab and avacopan, and how do their targeted actions impact treatment for various autoimmune conditions?

Without treatment from complement inhibitors, the 10-year survival rate for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) is just 65% [1.3.3]. Eculizumab revolutionized treatment for this and other rare diseases. But **how does Eculizumab work** to achieve this?